[1] NCD Risk Factor Collaboration(NCD-RisC).Trends in adult body-mass index in 200 countries from 1975 to 2014:a pooled analysis of 1698 population-based measurement studies with 19.2 million participants[J]. Lancet, 2016, 387(10026):1377-1396.
[2] BESSESEN D H, VAN GAAL L F.Progress and challenges in anti-obesity pharmacotherapy[J]. Lancet Diabetes Endocrinol, 2018, 6(3):237-248.
[3] ANDERSEN A, LUND A, KNOP F K, et al. Glucagon-like peptide 1 in health and disease[J]. Nat Rev Endocrinol, 2018, 14(7):390-403.
[4] DRUCKER D J.Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab, 2018, 27(4):740-756.
[5] KADOUH H, CHEDID V, HALAWI H, et al. GLP-1 analog modulates appetite, taste preference, gut hormones and regional body fat stores in adults with obesity[J]. J Clin Endocrinol Metab, 2020, 105(5):1552-1563.
[6] ASTRUP A, RÖSSNER S, VAN GAAL L, et al. Effects of liraglutide in the treatment of obesity:a randomised, double-blind, placebo-controlled study[J]. Lancet, 2009, 374(9701):1606-1616.
[7] AHRÉN B, ATKIN S L, CHARPENTIER G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials[J]. Diabetes Obes Metab, 2019, 20(9):2210-2219.
[8] O'NEIL P M, BIRKENFELD A L, MCGOWAN B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity:a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial[J]. Lancet, 2018, 392(10148):637-649.
[9] FENG P, YU D M, CHEN L M, et al. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients[J]. Acta Pharmacol Sin, 2015, 36(2):200-208.
[10] MAGKOS F, FRATERRIGO G, YOSHINO J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity[J]. Cell Metab, 2016, 23(4):591-601.
[11] EBERT S M, AL-ZOUGBI A, BODINE S C, et al. Skeletal muscle atrophy:discovery of mechanisms and potential therapies[J]. Physiology, 2019, 34(4):232-239.
[12] HYATT H, DEMINICE R, YOSHIHARA T, et al. Mitochondrial dysfunction induces muscle atrophy during prolonged inactivity:a review of the causes and effects[J]. Arch Biochem Biophys, 2019(662):49-60.
[13] ABELLAN VAN KAN G.Epidemiology and consequences of sarcopenia[J]. J Nutr Health Aging, 2009, 13(8):708-712.
[14] VON HAEHLING S, MORLEY J E, ANKER S D.An overview of sarcopenia:facts and numbers on prevalence and clinical impact[J]. J Cachexia Sarcopenia Muscle, 2010, 1(2):129-133.
[15] PERNA S, GUIDO D, BOLOGNA C, et al. Liraglutide and obesity in elderly:efficacy in fat loss and safety in order to prevent sarcopenia.A perspective case series study[J]. Aging Clin Exp Res, 2016, 28(6):1251-1257.
[16] 张雨丹, 刘仕群, 范存霞, 等.胰高血糖素样肽1受体激动剂对2型糖尿病合并超重/肥胖患者不同部位脂肪分布及肌肉含量的影响[J]. 南方医科大学学报, 2019, 39(4):450-455.
[17] ISHII S, NAGAI Y, SADA Y, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes:a prospective case series[J]. J Clin Med Res, 2019, 11(3):219-224.
[18] IKEJIMA S, KONDO S, SAKAI T, et al. Novel approach to sarcopenia in diabetic patients treated with GLP-1 receptor agonists(GLP-1RA)[J]. Diabetes, 2018, 67(Suppl 1):673.
[19] BLUNDELL J, FINLAYSON G, AXELSEN M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity[J]. Diabetes Obes Metab, 2017, 19(9):1242-1251.
[20] FENG W H, BI Y, LI P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease:a randomized trial[J]. J Diabetes Investig, 2019, 10(2):399-407.
[21] SEKO Y, SUMIDA Y, TANAKA S, et al. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Hepatol Res, 2017, 47(11):1206-1211.
[22] YIN T T, BI Y, LI P, et al. Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients:a randomized controlled trial[J]. Nutr Metab(Lond), 2018, 15:67.
[23] MCCRIMMON R J, CATARIG A M, FRIAS J P, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised controlled clinical trial[J]. Diabetologia, 2020, 63(3):473-485.
[24] LI C J, YU Q, YU P, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients[J]. Cardiovasc Diabetol, 2014, 13:36.
[25] XU F, CAO H, CHEN Z, et al. Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice[J]. Int J Obes(Lond), 2020, 44(4):937-947.
[26] HONG Y, LEE J H, JEONG K W, et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy[J]. J Cachexia Sarcopenia Muscle, 2019, 10(4):903-918.
[27] GURJAR A A, KUSHWAHA S, CHATTOPADHYAY S, et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents[J]. Metab Clin Exp, 2020(103):154044.
[28] ABDULLA H, PHILLIPS B E, WILKINSON D J, et al. Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle[J]. Aging Cell, 2020, 19(9):e13202.
[29] HOUSTON D K, NICKLAS B J, DING J, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults:the Health, Aging, and Body Composition (Health ABC) Study[J]. Am J Clin Nutr, 2008, 87(1):150-155.
[30] ROZENTRYT P, VON HAEHLING S, LAINSCAK M, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers:a randomized, double-blind pilot study[J]. J Cachexia Sarcopenia Muscle, 2010, 1(1):35-42. |
